Atherosclerosis plus最新文献

{"title":"Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots","authors":"A.L. Peterson , V. Horner , M.R. Lasarev , X. Zhang , S.E. Humphries , R.D. Steiner , M. Benoy , J. Tumolo , P.K. Held , X. Shao","doi":"10.1016/j.athplu.2025.10.007","DOIUrl":"10.1016/j.athplu.2025.10.007","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 4"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatric Familial Hypercholesterolaemia database at a single tertiary centre: a review of patients managed under the paediatric lipid clinic at Hammersmith Hospital","authors":"P. Chua, L. Barton, C. Neuwirth, J. Cegla, A. David, S. Walji","doi":"10.1016/j.athplu.2025.10.015","DOIUrl":"10.1016/j.athplu.2025.10.015","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 8"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disclaimer Page","authors":"","doi":"10.1016/S2667-0895(25)00060-4","DOIUrl":"10.1016/S2667-0895(25)00060-4","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 2"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HEART UK 38th Annual Medical & Scientific conference","authors":"","doi":"10.1016/j.athplu.2025.10.002","DOIUrl":"10.1016/j.athplu.2025.10.002","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 1"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Earthworm fibrinolytic enzyme A and fibrin-derived peptide Bβ15-42 attenuate atherosclerosis via the VE-Cadherin signaling pathway","authors":"Xiaowei Yin ,&nbsp;Yajie Zhang ,&nbsp;Luyao Shi ,&nbsp;Junwen Xue ,&nbsp;Zhen Tian ,&nbsp;Chicheng Gong ,&nbsp;Fen Wang ,&nbsp;Yongjun Cao","doi":"10.1016/j.athplu.2025.10.023","DOIUrl":"10.1016/j.athplu.2025.10.023","url":null,"abstract":"<div><h3>Aim</h3><div>Earthworm fibrinolytic enzymes A (EFEa) is the main active component of earthworm fibrinolytic enzymes which possesses anticoagulant, fibrinolytic, and potential anti-atherosclerotic effects. However, the biological function and mechanism of action of EFEa remains unclear. This study aims to investigate the role of EFEa and the fibrin-derived peptide Bβ15-42 (Bβ15-42) in attenuating atherosclerosis by modulating endothelial adhesion and inflammation via the vascular endothelial (VE)-cadherin signaling pathway.</div></div><div><h3>Methods</h3><div>In this study, we established both a rabbit model of atherosclerosis and an in vitro endothelial cell model. Bβ15-42, EFEa, and rosuvastatin (ROS) were administered to evaluate their effects on atherosclerotic plaque formation and inflammatory responses. Plaque size and intimal thickening were evaluated using Oil Red O and hematoxylin-eosin (HE) staining. Fibrinogen deposition and VE-cadherin expression were analyzed via western blotting and immunohistochemistry. Furthermore, macrophage migration assays and CDH5-positive (CDH5⁺) human umbilical vein endothelial cell (HUVEC) models were utilized to investigate the effects of these compounds on inflammatory cell migration and VE-cadherin-mediated endothelial barrier function.</div></div><div><h3>Results</h3><div>Treatment with Bβ15-42, EFEa, and ROS significantly reduced atherosclerotic plaque formation and intimal thickening in the rabbit model of atherosclerosis (<em>P</em> &lt; 0.05). Both Bβ15-42 and EFEa significantly reduced fibrinogen deposition and inflammatory cell infiltration in the aortic tissue of atherosclerotic rabbits (<em>P</em> &lt; 0.05). Western blot and immunohistochemical analyses confirmed that Bβ15-42 and EFEa effectively up-regulated VE-cadherin expression (<em>P</em> &lt; 0.05). In vitro, Bβ15-42 and EFEa significantly inhibited fibrin-induced macrophage transmigration across endothelial cell monolayers, reducing migration by 83.3 % and 56.1 %, respectively (<em>P</em> &lt; 0.05, respectively).</div></div><div><h3>Conclusion</h3><div>EFEa and Bβ15-42 exert protective effects against atherosclerosis via the VE-cadherin pathway. Our findings lay the groundwork for further research into the anti-atherosclerotic mechanisms of EFEa, as well as its potential for future development and application.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 21-29"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145474234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Layered plaque in patients with chronic coronary syndrome","authors":"Takafumi Mito ,&nbsp;Daisuke Kinoshita ,&nbsp;Yoichiro Otaki ,&nbsp;Jun Goto ,&nbsp;Seisei Ra ,&nbsp;Hiroe Ono ,&nbsp;Taku Shikama ,&nbsp;Shingo Tachibana ,&nbsp;Shigehiko Kato ,&nbsp;Tetsu Watanabe ,&nbsp;Ik-Kyung Jang ,&nbsp;Masafumi Watanabe","doi":"10.1016/j.athplu.2025.11.002","DOIUrl":"10.1016/j.athplu.2025.11.002","url":null,"abstract":"<div><h3>Background</h3><div>Plaque disruption exposes thrombogenic substrates and triggers local thrombosis. When a fresh thrombus forms, endogenous antithrombotic mechanisms activate. The balance between these two pro- and antithrombotic mechanisms determines the outcome of plaque disruption. When thrombogenic stimuli outweigh the antithrombotic mechanisms, an occlusive thrombus forms, leading to acute coronary syndromes. When antithrombotic mechanisms dominate, a non-occlusive thrombus forms, contributing to the rapid progression of atherosclerosis. A layered or healed plaque can be identified using optical coherence tomography (OCT).</div></div><div><h3>Purpose</h3><div>The study aimed to investigate the association between atherothrombotic biomarkers and layered plaque at culprit lesions.</div></div><div><h3>Methods</h3><div>We analyzed 119 lesions in patients with chronic coronary syndrome who underwent OCT prior to percutaneous coronary intervention. Four groups of biomarkers were studied: antithrombotic, atherogenic, prothrombotic, and inflammatory. The layer index, defined as the mean layer arc multiplied by the layer length, was assessed using OCT.</div></div><div><h3>Results</h3><div>Patients were divided into tertiles based on each of the four groups. Among the four groups, only the antithrombotic biomarkers were significantly associated with the layer index (low vs. moderate vs. high: 0 vs. 517 vs. 719, <em>p</em> for trend = 0.037). This positive correlation remained significant after adjusting for confounders. In contrast, no association was found between the layer index and atherogenic, prothrombotic, or inflammatory biomarkers.</div></div><div><h3>Conclusions</h3><div>The antithrombotic mechanism appears to play a key role in layered plaque formation.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 47-52"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical trial experience using in vivo base editing medicines for cardiovascular disease that aim to durably lower LDL cholesterol after a single treatment","authors":"S.B. Vafai","doi":"10.1016/j.athplu.2025.10.010","DOIUrl":"10.1016/j.athplu.2025.10.010","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 6"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertriglyceridemia and pancreatitis: Prevention success with older lipid lowering medication in a case with comorbidities","authors":"E. Mohamed,&nbsp;I. Boughazi,&nbsp;E. Ward,&nbsp;A. Theodoraki,&nbsp;M. Feher","doi":"10.1016/j.athplu.2025.10.012","DOIUrl":"10.1016/j.athplu.2025.10.012","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 6-7"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lomitapide in paediatric patients with homozygous familial hypercholesterolaemia (HoFH) – Analysis of long-term (104-week) safety and efficacy from the APH-19 study","authors":"Phil Dawson ,&nbsp;Luis Masana ,&nbsp;Alberto Zambon ,&nbsp;Claus Peter Schmitt ,&nbsp;Christina Taylan ,&nbsp;Joenna Driemeyer ,&nbsp;Hofit Cohen ,&nbsp;Paola Sabrina Buonuomo ,&nbsp;Abdullah Alashwal ,&nbsp;Mohammed Al-Dubayee ,&nbsp;Naji Kholaif ,&nbsp;José Luis Diaz-Diaz ,&nbsp;Faouzi Maatouk ,&nbsp;Sergio Martinez-Hervas ,&nbsp;Brian Mangal ,&nbsp;Sandra Löwe ,&nbsp;Zsuzsanna Tamas","doi":"10.1016/j.athplu.2025.10.016","DOIUrl":"10.1016/j.athplu.2025.10.016","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 9"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertriglyceridaemic Pancreatitis, Unmet Needs and How to Address: Preliminary Data from a National Project","authors":"Atiqah Sapiyan ,&nbsp;Bilal Bashir ,&nbsp;Aye Aye Thant ,&nbsp;Goran Ahmed ,&nbsp;Anoushka Kammath ,&nbsp;Maryam Ferdousi ,&nbsp;Handrean Soran","doi":"10.1016/j.athplu.2025.10.020","DOIUrl":"10.1016/j.athplu.2025.10.020","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 10-11"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}